NasdaqGS - Nasdaq Real Time Price USD

Certara, Inc. (CERT)

11.98
+0.11
+(0.93%)
At close: May 9 at 4:00:00 PM EDT
12.05
+0.07
+(0.58%)
After hours: May 9 at 7:17:20 PM EDT
Loading Chart for CERT
  • Previous Close 11.87
  • Open 12.00
  • Bid 11.88 x 2300
  • Ask 12.08 x 2300
  • Day's Range 11.95 - 12.21
  • 52 Week Range 8.64 - 17.75
  • Volume 1,325,654
  • Avg. Volume 1,979,351
  • Market Cap (intraday) 1.944B
  • Beta (5Y Monthly) 1.57
  • PE Ratio (TTM) --
  • EPS (TTM) -0.02
  • Earnings Date Aug 4, 2025 - Aug 8, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 15.78

Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

www.certara.com

1,487

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CERT

View More

Performance Overview: CERT

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CERT
12.49%
S&P 500 (^GSPC)
3.77%

1-Year Return

CERT
29.78%
S&P 500 (^GSPC)
8.55%

3-Year Return

CERT
31.31%
S&P 500 (^GSPC)
41.81%

5-Year Return

CERT
59.93%
S&P 500 (^GSPC)
93.18%

Compare To: CERT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CERT

View More

Valuation Measures

Annual
As of 5/8/2025
  • Market Cap

    1.93B

  • Enterprise Value

    2.05B

  • Trailing P/E

    --

  • Forward P/E

    25.97

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.84

  • Price/Book (mrq)

    1.78

  • Enterprise Value/Revenue

    5.20

  • Enterprise Value/EBITDA

    24.54

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.67%

  • Return on Assets (ttm)

    1.12%

  • Return on Equity (ttm)

    -0.25%

  • Revenue (ttm)

    394.5M

  • Net Income Avi to Common (ttm)

    -2.62M

  • Diluted EPS (ttm)

    -0.02

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    180.51M

  • Total Debt/Equity (mrq)

    28.51%

  • Levered Free Cash Flow (ttm)

    71.36M

Research Analysis: CERT

View More

Company Insights: CERT

Research Reports: CERT

View More

People Also Watch